Cellectar Biosciences (CLRB) Expected to Announce Earnings on Wednesday

Cellectar Biosciences (NASDAQ:CLRB) will likely be issuing its quarterly earnings data before the market opens on Wednesday, March 26th. Analysts expect Cellectar Biosciences to post earnings of ($0.38) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Cellectar Biosciences Trading Down 2.9 %

NASDAQ CLRB opened at $0.37 on Monday. Cellectar Biosciences has a 12 month low of $0.22 and a 12 month high of $4.17. The stock has a market cap of $17.00 million, a price-to-earnings ratio of -0.21 and a beta of 0.96. The company’s 50 day moving average is $0.29 and its two-hundred day moving average is $1.09.

Wall Street Analyst Weigh In

CLRB has been the topic of a number of analyst reports. Oppenheimer restated a “market perform” rating on shares of Cellectar Biosciences in a research note on Wednesday, December 11th. LADENBURG THALM/SH SH started coverage on shares of Cellectar Biosciences in a report on Thursday, December 5th. They issued a “buy” rating and a $13.00 target price on the stock. Finally, StockNews.com began coverage on Cellectar Biosciences in a research note on Tuesday, March 18th. They set a “sell” rating for the company.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Cellectar Biosciences stock. Bank of America Corp DE boosted its stake in shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) by 25.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 206,783 shares of the biopharmaceutical company’s stock after buying an additional 41,704 shares during the quarter. Bank of America Corp DE owned approximately 0.45% of Cellectar Biosciences worth $62,000 as of its most recent SEC filing. Institutional investors own 16.41% of the company’s stock.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.